As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Abbott Laboratories: Arrowpoint Investment Partners Singapore Pte. Ltd., Wolverine Trading LLC, Squarepoint Ops LLC, Point72 Asset Management L.P., Man Group plc, Maven Securities LTD, Millennium Management LLC, Moore Capital Management LP, LMR Partners LLP, Group One Trading LLC, Eisler Capital Management Ltd., Cubist Systematic Strategies LLC, Capstone Investment Advisors LLC, Citadel Advisors LLC, Balyasny Asset Management L.P., Bank of America Corp DE, BNP Paribas Financial Markets, Jane Street Group LLC, Paloma Partners Management Co, Lido Advisors LLC, Tudor Investment Corp ET AL, Parallax Volatility Advisers L.P., Susquehanna International Group LLP, HAP Trading LLC, Concourse Financial Group Securities Inc., Marshall Wace LLP, PEAK6 LLC, Walleye Trading LLC, Walleye Capital LLC, Barclays PLC, Dymon Asia Capital Singapore PTE. LTD., Capital Fund Management S.A., Capula Management Ltd, Wells Fargo & Company MN, JPMorgan Chase & Co., Mirae Asset Securities USA Inc., Simplex Trading LLC, Twin Tree Management LP, Allianz Asset Management GmbH, Wolverine Asset Management LLC, IMC Chicago LLC, Wealth Enhancement Advisory Services LLC, and JPMorgan Chase & Co.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.